Vertex Pharmaceuticals is experiencing a period of significant growth with the recent FDA approval of Alyftrek, a new treatment for cystic fibrosis, and the upcoming decision on Suzetrigine, a non-opioid acute pain medication. These approvals have the potential to significantly expand the company's patient reach and revenue streams.
Standard Chartered's Geoffrey Kendrick predicts that Bitcoin's price might fall to the low $80,000s if it breaks below $90,000, considering it as a buying opportunity. The report discusses concerns about macro risks, including potential volatility due to expectations around the Trump administration, and the possible impact on major Bitcoin holders.
U.S. stocks closed higher on Tuesday, with the Dow Jones Industrial Average gaining more than 200 points, while the Utilities sector led the gains, rising 1.1%. Several individual stocks experienced significant price movements, with Firefly Neuroscience surging 88% and Phio Pharmaceuticals plummeting 52%.
Seaport analyst Jeff Cantwell downgraded Mastercard to Neutral due to limited revenue growth potential and lack of near-term catalysts, despite acknowledging the potential for earnings surprises in the Fintech sector. He prefers Visa due to its greater U.S. exposure and rising expectations for domestic economic growth.
Standard Chartered analyst Geoffrey Kendrick believes Bitcoin could fall to the low $80,000s if it decisively breaks below $90,000, but views such a dip as an "excellent medium-term buying opportunity." Despite potential near-term volatility driven by macro risks and the incoming Trump administration, Standard Chartered maintains its long-term bullish outlook for Bitcoin, targeting $200,000 by the end of 2025.